Hsiao noted the options are adalimumab, a tumor necrosis factor α inhibitor; secukinumab, an IL-17A inhibitor; and ...

In a retrospective study of 393 patients, 51.9% had at least 1 abnormal LFT during follow-up, but only 1.1% had elevations ...

Trotter said dermatologists should pay attention to locally advanced and metastatic cutaneous squamous cell carcinoma (cSCC).

Ahmad Naim, MD, discussed clinician education, long-term data, and what is next in alopecia areata, HS, and psoriasis.

She described the patient consult as the starting point for aesthetic care. It covers the patient’s history, motivation for seeking treatment, prior aesthetic procedures, keloid history, and herpes ...

The second day of Fall Clinical 2026 brought new psoriasis data on ixekizumab plus tirzepatide and 2-year icotrokinra results ...

For a patient with atopic dermatitis who is ready for systemic therapy, the first priority is getting them on one, Raj Chovatiya, MD, PhD, MSCI, told Dermatology Times in an interview at. “There ...

The recent FDA approval of remibrutinib (Rhapsido) for symptomatic dermographism (SD) gives clinicians an on-label option for a condition long managed with off-label therapies, Raj Chovatiya, MD, PhD, ...

Shannon Trotter, DO, discusses augmented intelligence in skin cancer detection, the approval of remibrutinib for symptomatic ...

No skin lesion flares occurred through 16 weeks after patients with an inadequate response to dupilumab switched, and itch ...

Personalized prescription skin care is not necessarily designed around a single diagnosis or endpoint. As patients’ skin changes, their treatment goals may shift as well—from ...

The National Eczema Association (NEA) has released the State of AD 2026 National Indicator Report, a Milliman analysis ...